GU Cancers 2019 | Non-clear cell kidney cancer trial updates: CALYPSO and KEYNOTE-427

Tracy Rose, MD, of UNC Health Care, Chapel Hill, NC, presents a detailed overview on the Phase II CALYPSO trial (NCT02819596) investigating the use of savolitinib and durvalumab in papillary renal cancer, and the Phase II KEYNOTE-427 study (NCT02853344) looking at the efficacy of pembrolizumab therapy in renal cell carcinoma (RCC). This video was recorded at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA.